Print Page

给 业 界 的 信
 
Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management (Letter to Healthcare Professionals) (English only)
 
 
 
附件:
  1. Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management (English only)  
Related Information:
The United Kingdom: Dupilumab (Dupixent▼): risk of ocular adverse reactions and ... 上载于 2022-11-30
 
back